{
    "clinical_study": {
        "@rank": "78864", 
        "arm_group": {
            "arm_group_label": "Liraglutide"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this study is to investigate the safety profile\n      of liraglutide (Victoza\u00ae) under normal conditions of use in Korean subjects with type 2\n      diabetes mellitus."
        }, 
        "brief_title": "Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with T2DM (Type 2 Diabetes Mellitus), including newly-diagnosed subjects,\n             who require treatment with Victoza\u00ae according to the clinical judgment of their\n             treating physician\n\n          -  Subjects (and/or parents or the subject's legally acceptable representative) who are\n             capable of giving study-specific signed informed consent before any collection of\n             information\n\n        Exclusion Criteria:\n\n          -  Subjects with a hypersensitivity to Victoza\u00ae or to any of the excipients\n\n          -  Subjects who are pregnant, breast feeding or have the intention of becoming pregnant\n             within the study periods\n\n          -  Subjects with personal or family history of medullary thyroid carcinoma (MTC)\n\n          -  Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Victoza\u00ae will be prescribed and titrated by the physician"
            }
        }, 
        "enrollment": {
            "#text": "3600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821846", 
            "org_study_id": "NN2211-3929", 
            "secondary_id": "U1111-1132-2221"
        }, 
        "intervention": {
            "arm_group_label": "Liraglutide", 
            "description": "Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).", 
            "intervention_name": "liraglutide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 29, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "137-920"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza\u00ae) in Subjects With Type 2 Diabetes Mellitus in Korea", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The incidence of SADRs (Serious Adverse Drug Reactions)", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821846"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HbA1c (Glycosylated haemoglobin) change", 
                "safety_issue": "No", 
                "time_frame": "Month 0, month 6"
            }, 
            {
                "measure": "Percentage of subjects reaching the target of HbA1c below 7.0%", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Change in body weight", 
                "safety_issue": "No", 
                "time_frame": "Month 0, month 6"
            }, 
            {
                "measure": "Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}